Stefano Colloca

Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.

ReiThera Srl is a contract development and manufacturing organization (CDMO) based in Rome, Italy. The Italian company specializes in technology and process development, as well as GMP manufacturing, to support the clinical translation of genetic vaccines and medicinal products for advanced therapies. ReiThera has extensive expertise in developing scalable processes for viral-vector manufacturing and has a consolidated experience in GMP production of various types of viral vectors. The company's state-of-the-art facility includes bioreactors of different scales, a filling suite, and quality control laboratories. ReiThera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. ReiThera Srl is dedicated to meeting the highest demand for the development, manufacture, and storage of viral vectors, drugs, and clinical samples. The company was founded in 2005 by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, and Stefano Colloca, who is also the CEO.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.